Markets Digest Divided Government as CVS Plans a Healthcare Breakup

S&P futures dropped sharply as midterm results came in, then recovered substantially. As of this morning, futures stood at around 7,669 — up roughly 73 points, or just under one percent. The initial decline reflected uncertainty about what a Democratic Congress means for corporate tax rates, regulation, and spending. The recovery reflects a second-order calculation: divided government typically produces fiscal gridlock, and gridlock tends to mean the status quo on taxes and regulation persists. For large-cap U.S. equities, that status quo is relatively comfortable.

The dollar is a different story. It is sliding toward a one-month low as traders bet that fiscal gridlock reduces the probability of deficit-expanding spending bills, which pulls Treasury yields lower, which reduces the interest rate differential that attracts foreign capital into dollar-denominated assets. Jon Ossoff's reelection in Georgia was reportedly the specific catalyst that crystallized the read — confirming the Senate was flipping — and the dollar moved on that confirmation. A sustained dollar weakening would make U.S. exports cheaper globally, make imports more expensive for American consumers, and affect the earnings of multinationals converting overseas revenues back into dollars.

CVS Health is reportedly planning to split off its pharmacy chain — the retail stores — from the rest of the company. Under the described structure, Aetna and Caremark, the pharmacy benefits manager, would remain together while the brick-and-mortar retail operation becomes a separate public company. CVS serves roughly 100 million people in some capacity, and the company has been under pressure from multiple directions simultaneously: squeezed pharmacy reimbursement rates, existential competition from mail-order and specialty pharmacies, and rising medical costs at Aetna, which CVS acquired for approximately 69 billion dollars in 2018.

The split would unwind the integration thesis that animated that acquisition. CVS argued that common ownership of insurance, drug benefits management, and pharmacy could coordinate care more efficiently and reduce costs. Separating the pharmacy from the insurance and PBM operations raises genuine consumer questions about whether that coordination is lost — or whether the thesis was primarily a narrative sold to investors rather than a realized operational reality.

For healthcare policy, the timing is notable. Democrats in Congress have been pushing for pharmaceutical pricing reforms, greater PBM transparency, and restrictions on vertical integration in healthcare. A CVS breakup might align with that agenda by reducing vertical concentration — or complicate oversight by creating more separately regulated entities. The company's earnings call later this week may formally announce the plan.